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Abstract We here describe the identification and characteriza-
tion of a novel bromodomain-containing protein, the bromodo-
main protein of 75 kDa (BP75). Initially, we identified BP75 in a
two-hybrid screening for proteins that interact with the first PDZ
(acronym for post-synaptic density protein PSD-95, Drosophila
discs large tumor suppressor DlgA and the tight junction protein
ZO-1) domain in protein tyrosine phosphatase-BAS-like (PTP-
BL). We found that BP75 is expressed ubiquitously and show
that both BP75 and a PTP-BL deletion mutant consisting of the
first PDZ domain are located mainly in the nucleus, although
cytoplasmic localization is also evident. Full-length PTP-BL, on
the contrary, is predominantly localized in the cytoplasm,
although some basal nuclear staining is observed. The described
molecular interaction may reflect a mechanism of coupling
submembraneous signalling events and nuclear events.
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1. Introduction
The accuracy of the signal transduction process, whereby
extracellular signals evoke a speci¢c cellular response, largely
relies on mechanisms that regulate steps in the transmembrane
transmission and the integration or divergence of signalling
pathways within the cells’ cytosol and nucleus. An important
mechanism to achieve speci¢city in signalling is the use of
sca¡old, anchoring and adapter proteins [1]. Such proteins
are considered organizers of multiprotein complexes, creating
‘signallosomes’ with specialized functions at restricted micro-
compartments [1]. Protein modules like src homology type 2,
src homology type 3, WW, LIM, WD, phosphotyrosine bind-
ing, pleckstrin homology and PDZ (acronym for post-synap-
tic density protein PSD-95, Drosophila discs large tumor sup-
pressor DlgA and the tight junction protein ZO-1) domains
form the basal building blocks and play an important role in
the architecture of signal transduction complexes [2].
The mouse protein tyrosine phosphatase-BAS-like (PTP-
BL) [3] or RIP [4] and the human homologue of this protein
named PTP-BAS [5], PTPL1 [6], PTP1E [7] or FAP-1 [8] have
several characteristics (Fig. 1) that make them potential or-
ganizers of signal transduction complexes. PTP-BL harbors a
FERM domain [9], a domain commonly found in cytoskele-
ton-associated proteins like ezrin, radixin, moesin, merlin and
talin [10], that directs the putative multiprotein complex to its
highly restricted submembraneous site (Cuppen et al., submit-
ted). Furthermore, PTP-BL contains ¢ve PDZ domains, small
(about 90 amino acids (aa)) protein modules [11] that have
now been identi¢ed in many members of a diverse group of
proteins [12] and can mediate protein-protein interactions
[13,14]. PDZ domains associate with transmembrane proteins
[15], cytoskeletal components [16] and signal transduction en-
zymes [14]. The ¢ve PDZ domains in PTP-BL may thus en-
able the formation of large multiprotein complexes in which
the phosphotyrosine phosphatase action of PTP-BL itself can
be combined with potential downstream substrates, competi-
tor signalling proteins and putative upstream regulatory mol-
ecules. Indeed, proteins that interact with PDZ domains of
PTP-BL have already been described. The GTPase-activating
protein for Rho, phosphatase-associated Rho GTPase-1, in-
teracts with PDZ-IV [17], the small adaptor protein RIL, that
is an in vitro substrate for PTP-BL, interacts with both PDZ-
II and IV [18] and B-type ephrins can bind to PDZ-IV [19].
The Fas receptor has also been described to bind to PDZ-II in
the human homologue of PTP-BL [8,20], but this interaction
could not be con¢rmed in mouse [21]. Recently, PDZ-I was
found to interact with IUBK [22], suggesting a regulatory role
for PTP-BL in transcriptional control via NF-UB.
We here report on the identi¢cation of yet another protein,
the novel bromodomain-containing protein of about 75 kDa
(BP75), that interacts with PDZ-I in PTP-BL. The bromodo-
main, originally described as an evolutionary highly conserved
80 aa domain in human, Drosophila and yeast proteins [23], is
now de¢ned as a conserved sequence of approximately 110 aa
that is found in over 40 proteins [24]. Many of these proteins
are involved in transcriptional control and recently, structural
data from the bromodomain of the histone-acetyltransferase
(HAT) co-activator P/CAF provided evidence that bromodo-
mains can bind acetylated lysines [25]. Bromodomains may
thus be important determinants for targetting proteins or pro-
tein complexes to speci¢c chromosomal sites by binding to
acetylated histones and thereby regulating transcriptional ac-
tivity. Our results suggest that BP75 may have a role in link-
ing signalling events in the PTP-BL multiprotein complex and
the nucleus.
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2. Materials and methods
2.1. Two-hybrid interaction trap
Plasmid DNAs, the yeast strain EGY48 and the HeLa cell cDNA
library used for the interaction trap assay were kindly provided by Dr
Roger Brent and colleagues (Massachusetts General Hospital, Boston,
MA, USA) and used as described [26]. The construction of the PTP-
BL PDZ, RIL-PDZ, nNOS PDZ and SAP-PDZ baits has been de-
scribed previously [18,27]. For two-hybrid interaction assays, plasmids
were introduced in yeast strain EGY48 (MATa trp1 ura3 his3
LEU2 : :pLexAop6-LEU2) containing the plasmid pSH18-34, which
includes the reporter lacZ gene, and interactions were validated by
growth and blue coloring on minimal agar plates lacking histidine,
tryptophan, uracil and leucine, which contain 2% galactose, 1% ra⁄-
nose and 80 Wg/ml X-gal, bu¡ered at pH 7.0. Comparison of candi-
date prey cDNA sequences with database entries was done using the
BLAST program [28]. Mouse BP75 prey constructs containing the
fragment corresponding to the shortest human prey insert
(mBP75C, aa 323^651), the C-terminus of BP75 (BP-Cter, aa 620^
651) and the C-terminal half of BP75 lacking the C-terminus (BP-
vCter, aa 362^622) were generated by PCR using speci¢c primers
with either EcoRI or XhoI restriction enzyme recognition sites, using
mouse full-length BP75 cDNA (AF084259) as a template. The result-
ing fragments were cloned in-frame in an EcoRI and XhoI-digested
pJG4-5 prey vector [26]. All constructs generated by PCR were
checked for absence of mutations by DNA sequencing.
2.2. Isolation and characterization of mouse BP75 cDNAs
The 1.2 kb BP#3 insert was isolated, labelled radioactively by ran-
dom priming and used to screen a mouse brain V-ZAPII cDNA phage
library (Stratagene, La Jolla, CA, USA) following standard proce-
dures. Resulting phages were plaque-puri¢ed and inserts were rescued
as pBluescript SK3 plasmids according to the manufacturer’s proto-
cols. Nucleotide sequences were determined by double-stranded DNA
dideoxy sequencing using T3 and T7 sequencing primers on rescued
plasmids and subclones derived thereof. Sequences were aligned with
Multalin [29] using the Blosum62 comparison table and annotated
with Genedoc (shareware, version 2.2.005 [30]).
2.3. RNA expression studies
Total RNA from several mouse (strain C57BL/6) tissues was pre-
pared as described previously [21]. Fifteen Wg RNA was loaded on a
1% formamide agarose gel and after electrophoresis, the RNA was
transferred to a nylon membrane (Hybond-N, Amersham) according
to standard procedures. Complete mouse BP75, PTP-BL and
GAPDH cDNAs were radioactively labelled by random priming
and used as probes for hybridization as described [21]. RNA in situ
hybridization on C57BL/6 mouse embryo cryosections was according
to previously published protocols [3]. To generate ‘sense’ and ‘anti-
sense’ RNA probes, the mouse BP75 cDNA pBluescript SK-based
plasmid was linearized with XhoI and NotI, respectively, and used
for in vitro transcription by T7 or T3 RNA polymerase, respectively.
Both probes were labelled with [K-35S]UTP (400 Ci/mmol, Amersham)
to a speci¢c activity of s 109 dpm/Wg.
2.4. Expression plasmid constructions
Restriction fragments encoding aa stretches 1056^1284 and 1002^
2018 of PTP-BL (Z32740) encompassing PDZ-I and PDZ-I-V, respec-
tively, were cloned into a modi¢ed version of the eukaryotic expres-
sion vector pSG5 [31] that contains an initiator AUG codon at the
multiple cloning site. A construct for the expression of an epitope-
tagged version of mouse BP75 was generated as follows. Using a
subcloned SmaI fragment of BP75 as template, the 5P-end of the
BP75 open reading frame was PCR-ampli¢ed with a speci¢c oligonu-
cleotide (5P-CGAATTCATGGGCAAGAAGCACAAG-3P, introduc-
ing an EcoRI site directly in front of the start codon) and the vector-
speci¢c T7 oligonucleotide. The resulting 0.2 kb fragment was di-
gested with EcoRI and XmaI and used together with a 1.9 kb
XmaI-XhoI restriction fragment of BP75 in a three-way ligation into
the EcoRI-XhoI-digested pMyc vector. pMyc is a pCDNA3-derived
vector in which at the 5P-end of the pCDNA3 (Invitrogen) multiple
cloning site, a synthetic DNA fragment was introduced that entails an
initiator AUG codon followed by the cMyc epitope tag and an EcoRI
site. Full-length PTP-BL [3] was subcloned as a NotI-XhoI restriction
fragment in pCDNA3.
2.5. Immunoprecipitation and Western blotting
COS-1 cells were cultured in DMEM/10% fetal calf serum (FCS).
For each assay, 1.5U106 cells were electroporated at 0.3 kV and 125
WF using the Bio-Rad GenePulser with a 4 mm electroporation cu-
vette, in 200 Wl of phosphate-bu¡ered saline (PBS) containing 10 Wg of
supercoiled plasmid DNA. Cells were plated on a 10 cm dish and
Fig. 1. The C-terminal half of BP75 interacts with the ¢rst PDZ motif in PTP-BL. Schematic representation of the protein segments as they
are used in the two-hybrid interaction trap. Depicted are (A) the PDZ-I segment of PTP-BL used as bait and (B) the BP75 segments retrieved
from the HeLa cDNA library (BP#3 and BP#6) and used as deletion constructs. The numbers corresponding to the ¢rst and last aa positions
in the PTP-BL (Z32740) and BP75 (AF084259) segments are shown in parentheses, followed by a quantitative interpretation of the two-hybrid
interaction results with PDZ-I. ++, strong interaction; þ , very weak interaction. Band 4.1-like domain, hatched box; PTPase, open box; PDZ
domains, black ovals; bromodomain, gray box; BYC homology domain (see text), stippled box. BP75 co-precipitates with PDZ domains of
PTP-BL (C). COS-1 cells were co-transfected with a construct encoding cMyc epitope-tagged BP75 and a construct encoding the ¢ve PDZ do-
mains of PTP-BL (BL-PDZ-I^V) or empty vector as a control. Western blotting using an K-cMyc antibody detected a 75 kDa protein in the
total cell lysates (left panel). After immunoprecipitation using a polyclonal antiserum directed against the ¢rst PDZ domain of PTP-BL (K-BL-
PDZ-I), co-precipitation of cMyc epitope-tagged BP75 with the ¢ve PDZ domains of PTP-BL is shown (right panel). No co-precipitation of
BP75 is observed in lysates of COS cells co-transfected with empty vector.
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cultured for 24 h in DMEM/10% FCS. Cells were washed with cold
PBS and lysed on a plate with 550 Wl ice-cold RIPA bu¡er (50 mM
Tris, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS,
0.5% DOC, 1 mM PMSF and protease inhibitor cocktail; Boehr-
inger). After a 1 h incubation on ice, the lysate was centrifuged for
10 min at 10 000Ug at 4‡C and proteins in 50 Wl of the lysate were
separated for further analysis. After addition of the polyclonal anti-
body K-BL-PDZ-I (a⁄nity-puri¢ed, 50Udiluted; [18]) and overnight
rotation at 4‡C, 50 Wl of protein A-Sepharose CL-4B (Pharmacia) was
added and incubation was prolonged overnight. The Sepharose beads
with immunobound proteins were washed four times with 1 ml RIPA
lysis bu¡er and boiled for 5 min in 50 Wl of 2Usample bu¡er (100 mM
Tris-HCl, pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.2% bromophe-
nol blue, 20% glycerol). Fifteen Wl of lysates and immunobound pro-
teins was resolved on 8% polyacrylamide gels and transferred to nitro-
cellulose membranes by Western blotting. Blots were blocked using
5% non-fat dry milk in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl and
0.05% Tween 20 (TBST). Cell culture supernatant of the K-cMyc
hybridoma 9E10 [32] was used to detect co-precipitation of epitope-
tagged BP75. Incubations with primary and secondary antibodies (1
h, 10 000U diluted peroxidase-conjugated goat anti-mouse IgG,
Pierce) and subsequent washes were done in TBST at room temper-
ature. Labelled bands were visualized using freshly prepared chemilu-
minescent substrate (100 mM Tris-HCl, pH 8.5, 1.25 mM p-coumaric
acid (Sigma), 0.2 mM luminol (Sigma) and 0.009% H2O2).
2.6. Cell transfection
Mouse embryonic ¢broblasts (NIH 3T3) and MDCK type II cells
(a kind gift of K. Ekroos, Heidelberg, Germany) were cultured in
DMEM (Gibco BRL, Gaithersburg, MD, USA), supplemented with
10% FCS (Zellbiologische Produkte, St. Salvator, Germany). Prior to
transfection, cells were seeded onto 14 mm diameter glass coverslips
(Menzel-Glaser, Germany) in 24 well cell culture plates. Transfection
mix was made by adding 0.3 Wg supercoiled plasmid DNA to 2 Wg
DAC-30 (Eurogentec, Seraing, Belgium) in 150 Wl OptiMEM (Gibco
BRL, Gaithersburg, MD, USA) and incubating for 30 min at room
temperature. After replacing the culture medium on the cells (at 30^
50% con£uency) with 150 Wl fresh DMEM containing 10% FCS, the
transfection mix (150 Wl) was added to the cells. Following a 5 h
incubation at 37‡C, the medium was replaced with fresh DMEM
containing 10% FCS and incubation was prolonged overnight. Cells
were subsequently used for immuno£uorescence.
2.7. Immuno£uorescence and microscopy
All solutions are prepared in PBS and incubations were performed
at room temperature in the presence of 1% goat serum. Cells were
¢xed for 20 min in 2% paraformaldehyde, permeabilized with 0.5%
NP-40 and then, free aldehyde groups were quenched for 10 min in
0.1 M glycine. Fifty Wl of a 1:2 dilution of monoclonal mouse K-cMyc
(hybridoma culture supernatant, 9E10; [32]) and a 1:50 dilution of
a⁄nity-puri¢ed polyclonal rabbit K-BL-PDZ-I (directed against the
¢rst PDZ domain of PTP-BL; [18]) was used for the 1 h incubation
with primary antibody. After thoroughly rinsing in PBS, cells were
incubated for 5 min with the second antibodies, 50 Wl of a 1:75
dilution Texas red-conjugated A⁄niPure goat anti-mouse IgG and a
1:75 dilution £uorescein-conjugated A⁄niPure goat anti-rabbit IgG
(both from Jackson ImmunoResearch Laboratories, West Grove, PA,
USA). In cases where DNA was stained with propidium iodine (5 Wg/
ml), the £uorescein-conjugated A⁄niPure goat anti-mouse IgG (Jack-
son ImmunoResearch Laboratories, West Grove, PA, USA) was used
as second antibody. Finally, the coverslips were rinsed in PBS and
water and mounted on slides by inversion over 5 Wl Mowiol mountant
(Sigma Chemical). Cells were examined using a confocal laser scan-
ning microscope (MRC1000, Bio-Rad).
3. Results
3.1. BP75 interacts with the ¢rst PDZ motif in PTP-BL
Several candidate proteins interacting with the ¢rst PDZ
domain of PTP-BL (Fig. 1A) were identi¢ed in a yeast two-
hybrid interaction trap screening of a HeLa cell cDNA li-
brary. Four clones out of 0.9 U106 transformants remained
positive after re-introduction into freshly prepared yeast cells
containing appropriate bait and reporter plasmids. Two
clones, BP#3 and BP#6 with inserts of 1.2 and 1.1 kb, respec-
tively, were found to represent independent cDNAs from the
same messenger RNA (Fig. 1B). Comparison of the aa se-
quences of their predicted protein products with database en-
tries did not reveal any similarity to known proteins. Further-
more, nucleotide database searches with the BP#3 cDNA
insert showed only homology to expressed sequence tags
from various tissues, indicating that BP#3 encodes a novel
ubiquitously expressed protein. Since PTP-BL is of mouse
origin and the interacting clones were obtained from a human
cDNA library, we isolated mouse cDNAs that are homolo-
gous to BP#3 (see below) and con¢rmed the two-hybrid in-
teraction using the cDNA segment encoding the C-terminal
half of the mouse protein (mBP75C, aa 323^651, Fig. 1B).
Since several PDZ motifs have been described to speci¢cally
recognize short C-terminal peptides [33,34], we tested deletion
mutants of mBP75 (Fig. 1B) to delineate the interaction inter-
face. Deletion of the C-terminus (mBP-vCter, aa 362^622)
almost completely abolished the interaction, but presence of
the C-terminus proper (mBP-Cter, aa 620^651) is not su⁄-
cient for a strong interaction (Fig. 1B). None of the mBP75
constructs interacts with an empty bait or with other PDZ
domains of PTP-BL (not shown). Furthermore, no interaction
was observed with the PDZ domain of RIL, nNOS or the
second PDZ domain of SAP90 (not shown).
To obtain independent evidence for the interaction between
BP75 and PTP-BL, we co-transfected mammalian epithelial
cells (COS-1) with an expression construct encoding Myc epit-
ope-tagged full-length BP75 and a construct encoding the ¢ve
PDZ domains of PTP-BL (BL-PDZ-I^V) or, as a control, the
empty expression vector. Speci¢c co-precipitation of anti-Myc
detectable full-length BP75 was demonstrated for BL-PDZ-I^
V (Fig. 1C) when using an antibody against BL-PDZ-I [18],
con¢rming the results obtained in the yeast two-hybrid inter-
action trap.
3.2. Isolation and characterization of mouse BP75 cDNA
clones
Sequence analysis of BP#3 and BP#6 cDNA inserts re-
vealed that only partial sequence information of the encoded
protein was obtained. To acquire additional sequence data
and at the same time have a more complete tool to study
the biological function of the encoded protein, we searched
for full-length cDNAs by screening a mouse fetal brain cDNA
library using the human BP#3 cDNA insert as a probe. Two
clones, with inserts of 1.8 and 2.4 kb, respectively, were ob-
tained. The 2361 bp insert of the longest cDNA (GenBank
accession number AF084259) most probably represents a full-
length cDNA since Northern blot analysis revealed a tran-
script of about 2.5 kb in length (Fig. 3A). The smaller
cDNA was found to be identical to the last 1804 bp of this
clone. Sequence analysis revealed a polyadenylation sequence
located 18 bp upstream of the poly-A tract and an open read-
ing frame that speci¢es a 651 aa polypeptide (Fig. 2A). The
predicted protein was found to contain a bromodomain (see
below) and has a molecular mass of about 75 kDa and there-
fore, we termed it BP75. BP75 has overall homology with only
a single protein present in the databases, the hypothetical
Caenorhabditis elegans protein C01H6.7 (Z71258; [35]). Se-
quence alignment shows that there are two domains of high
homology between these proteins (Fig. 2A). The ¢rst domain
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was found to encode a bromodomain (Fig. 2B; [23]). The
evolutionary highly conserved bromodomains (about 110 aa)
have now been identi¢ed in more than 40 di¡erent proteins,
many of which are involved in transcriptional activation [24].
Database comparison and sequence alignment (Fig. 2B) reveal
that the BP75 bromodomain displays the highest similarity to
the bromodomain in C01H6.7 and a human protein called
peregrin or BR140 (JC2069; [36]). The second stretch of
high homology between BP75 and C01H6.7 of about 80 aa
has no clear similarity with any of the known bromodomain-
containing proteins nor any other known protein except for a
yeast protein called YN92 (Fig. 2C). The sequence of this
segment has 70 and 34% similarity between BP75 and
C01H6.7 and YN92, respectively. Therefore, we will refer to
this segment as BYC domain, for its presence in BP75, YN92
and C01H6.7. YN92 is a putative transcription regulatory
protein from yeast that contains a DNA binding Zn(2)-
Cys(6) fungal-type binuclear cluster domain [37] for which
no homology exists in BP75. Analysis of BP75 using the PRO-
SITE protein motif database predicts two consensus tyrosine
phosphorylation sites (aa 14 and 430), two partially overlap-
ping bipartite nuclear localization signals (aa 66^83 and 80^
97; [38]) and several potential protein kinase C and casein
kinase II phosphorylation sites. This suggests a nuclear local-
ization for BP75 and indicates that the protein may be post-
translational modi¢ed by both serine/threonine and tyrosine
phosphorylation.
3.3. BP75 expression pattern
The observed interaction between BP75 and PTP-BL can
only be of biological signi¢cance when both genes are co-ex-
pressed in at least some tissues. Therefore, the BP75 cDNA
insert (Fig. 3A, upper panel) and full-length PTP-BL cDNA
(Fig. 3A, second panel) were used to probe a Northern blot of
total RNA from several di¡erent mouse tissues. A BP75 tran-
script of about 2.5 kb is highly expressed in all tissues exam-
ined, with the highest levels in lung, stomach and thymus. The
8.5 kb PTP-BL transcript has a more restricted expression
pattern and is most abundant in lung, kidney, testis, stomach
and skin. To further delineate the BP75 expression pattern, we
used an antisense BP75 RNA probe for in situ hybridization
on mouse embryo cryosections. BP75 expression is found
throughout development in all embryonic stages (10.5^18.5
dpc) analyzed (not shown). In 16.5 dpc embryos, BP75 is
ubiquitously expressed, with the highest expression levels in
thymus, lung, liver, colon and the spinal cord (Fig. 3B, middle
Fig. 3. Tissue distribution of BP75 and PTP-BL. (A) Northern blot analysis of total RNA from mouse tissues for BP75 (upper panel) and
PTP-BL (second panel). Expression analysis of the housekeeping gene GAPDH (third panel) was used as a control. As another control for
RNA loading, rRNA bands in total RNA on an ethidium bromide-stained gel are shown (bottom panel). BP75 is expressed ubiquitously in all
tissues examined, whereas PTP-BL is highly expressed in lung, kidney, testis, stomach and skin and to a lower level in brain and thymus.
(B) BP75 RNA in situ hybridization on 16.5 dpc mouse embryo sections. A bright ¢eld image (left panel) and dark ¢eld images using an anti-
sense BP75 RNA probe (middle panel) and a sense BP75 probe (right panel) on 16.5 dpc mouse embryo cryosections are shown. BP75 is ex-
pressed throughout the whole embryo with the highest expressions in thymus, lung, liver, colon and the spinal cord. Furthermore, a high ex-
pression is also observed in salivary glands, vibrisae and skin. T, thymus; lu, lung; li, liver; g, gut; sc, spinal cord; sg, salivary glands;
vi, vibrisae; h, heart; nc, nasal cavity. Bars, 1 mm.
Fig. 2. Sequence comparison of the BP75 protein. (A) The complete BP75 protein sequence (AF084259) was aligned with the predicted protein
C01H6.7 from the C. elegans contig C01H6 (Z71258). Identical aa are shown on a black background and similar aa are indicated on a gray
background. The bromodomain and BYC domain are single and double-underlined, respectively, and the predicted nuclear localization signals
are indicated by a stippled line. The vertical arrows indicate the start of the clones identi¢ed in the two-hybrid interaction trap (BP#3 and
BP#6, respectively). (B) The bromodomain of BP75 is shown, aligned with bromodomains from di¡erent proteins. The original 80 aa bromodo-
main motif [23] and the secondary structure as predicted from a multiple alignment of 37 proteins [24] are indicated at the bottom. The aligned
proteins are the hypothetical C. elegans protein C01H6.7 (Z71258), human peregrin or BR140 (JC2069), Tetrahymena thermophila HAT A1
(U47321), mouse CREB binding protein (CBP, P45481), mouse RING3 (D89801), human transcription initiation factor TFIID, 250 kDa sub-
unit (TAFII-250, P21675) and human SNF2K (S45251). The numbers on the left and right of the peptides indicate the corresponding N- and
C-terminal aa positions in the database entry. Symbols used in the consensus sequence: $, positive charge (K,R); !, (M,L,I,V); %, (S,T);
#, (Y,F). (C) Multiple alignment of the BYC domain of BP75 (AF084259), C01H6.7 (Z71258) and YN92 (P53749).
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panel). Signi¢cant expression is also found in salivary glands,
vibrissae and skin. No positive signal was obtained when a
BP75 sense RNA probe was used (Fig. 3B, right panel).
3.4. BP75 and PTP-BL protein localization
To study the subcellular distribution of both interactors,
full-length cMyc epitope-tagged BP75 was expressed transi-
ently in NIH 3T3 ¢broblasts together with either the ¢rst
PTP-BL PDZ domain or full-length PTP-BL. Using £uores-
cent double-labelling, we found that BP75 localizes predom-
inantly to the nucleus (Fig. 4A,C), as does BL-PDZ-I (Fig.
4B), although cytoplasmic staining is also evident in some
cells. There is an interesting correlation between the BP75
and BL-PDZ-I nuclear and cytoplasmic location in double-
transfected cells. In cells where BP75 is located in the cyto-
plasm, BL-PDZ-I is also cytoplasmically localized. Further-
more, at a higher magni¢cation, a typical distribution pattern
that is indicative for a nucleoplasmic localization becomes
obvious for both BP75 (Fig. 4A, insert) and BL-PDZ-I (Fig.
4B, insert). It is interesting to note that PTP-BL PDZ-I is the
only domain out of seven PDZ domains tested by transient
expression that localizes to the nucleus (E.C., unpublished
observations). The BP75 localization hardly overlaps with
that of the complete PTP-BL protein, although both cytoplas-
mic (Fig. 4C,D, cell indicated by #) and nuclear (Fig. 4C,D,
indicated by *) co-localization can occasionally be observed.
Hardly any mitotic cells could be found that express BP75.
However, the few cells observed showed very faint cytosolic
staining, largely excluding the area of the chromosomes (Fig.
4E,F). These observations suggest that BP75 is degraded be-
fore or during mitosis.
4. Discussion
We report here on the identi¢cation of two independent
clones encoding the C-terminal part of a novel bromodo-
main-containing protein, BP75, that speci¢cally interact with
the ¢rst PDZ domain of the protein tyrosine phosphatase
PTP-BL. It is becoming increasingly clear that PDZ domains,
as they occur in PTP-BL and a variety of other proteins [12],
are protein-protein interaction modules that generally bind to
short C-terminal peptides [33,34]. In line with this, we found
that deletion of the last 29 aa of BP75 almost completely
abolished any detectable interaction. In contrast, the last 30
aa of BP75 alone are not su⁄cient for a strong interaction.
Moreover, the last three residues of BP75 (-DAS*) do not
Fig. 4. BP75 and PTP-BL subcellular localization. cMyc-tagged BP75 was transiently co-expressed with the ¢rst PDZ domain of PTP-BL (A, B)
or with full-length PTP-BL (C, D) in NIH 3T3. Cells were double-labelled for BP75 (A, C) and PTP-BL PDZ-I (B) or full-length PTP-BL (D).
The inserts in (A) and (B) show an enlargement of the cell indicated with an arrow. In cells co-expressing BP75 and PTP-BL, both cytoplasmic
(*) and nuclear (#) co-localization is observed (C, D). In mitotic cells, only weak BP75 staining can be observed (E) and excludes the area of
the chromosomes as detected by propidium iodine staining (F). Bars, 10 Wm.
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resemble any of the known consensus motifs for PDZ recog-
nition [33] and screening of a two-hybrid random peptide
library to identify a consensus C-terminal peptide target se-
quence for PTP-BL PDZ-I did not result in interacting pep-
tides (E.C., M.v.H., unpublished work), whereas the same
approach was successful for the neuronal NOS PDZ domain
[27]. Taken together, this argues against a simple model in
which PDZ domains uniquely engage in C-terminal peptide
binding. Perhaps additional protein segments are necessary
for a strong interaction to occur. Interestingly, secondary
structure prediction suggests the presence of coiled-coil ele-
ments in the C-terminal half of BP75 (aa 534^565) and per-
haps dimerization via these structures may be a prerequisite
for interaction with BL-PDZ-I. Alternatively, BL-PDZ-I may
belong to a subset of PDZ domains that is not capable of
recognizing C-terminal peptides. Indeed, evidence is accumu-
lating that internal peptide sequences may equally well serve
as targets for recognition by PDZ domains [16,18,39,40] and
recently, a molecular basis for internal peptide recognition
was provided by the structure of the nNOS-syntrophin com-
plex [41]. In line with this, Maekawa and coworkers found
that IUBK associates with PDZ-I in PTP-BAS through a
stretch of N-terminal ankyrin repeats [22].
The interaction identi¢ed in the yeast two-hybrid interac-
tion trap was con¢rmed in an independent assay under con-
ditions that better resemble the in vivo situation. Complete
BP75 can be co-immunoprecipitated from transfected mam-
malian cells with a protein segment encompassing the ¢ve
PDZ domains of PTP-BL (Fig. 1C). Unfortunately, we were
unable to show an interaction between full-length proteins due
to the very low PTP-BL protein levels that were obtained in
our transfection studies (E.C., unpublished observations).
Northern blot and RNA in situ hybridization analysis show
an ubiquitous expression of BP75 mRNA (Fig. 3), suggesting
a structural or general function for the protein. In contrast,
PTP-BL expression is restricted to epithelial tissues (Fig. 3,
[3,18]), restraining the biological function for the observed
interaction.
Transfection studies, as shown in Fig. 4, reveal BP75 to
have predominantly a nuclear location. This is in keeping
with the presence of the bromodomain [23,24] and the bipar-
tite nuclear localization signals in the product speci¢ed by the
full-length mouse cDNA. Bromodomains have been proposed
to mediate protein-protein interactions in the nucleus, thereby
in£uencing the assembly and/or activity of multiprotein com-
plexes [23,24]. Indeed, GCN5, a putative transcriptional
adapter in humans and yeast, was found to bind to DNA-
dependent protein kinase holoenzyme via its bromodomain,
resulting in phosphorylation of GCN5 and inhibition of its
HAT activity [42]. Furthermore, it was recently shown that
the bromodomain of yeast Gcn5p can interact in vitro with
the N-terminus of histone H4 [43] and the solution structure
of the bromodomain of the HAT co-activator P/CAF (p300/
CBP-associated factor) revealed speci¢c recognition of acetyl-
ated lysines by this domain [25]. These observations suggest
that bromodomain-containing proteins may be important for
the assembly and activity of multiprotein complexes at speci¢c
chromosomal sites, thereby regulating chromatin remodelling
and transcriptional activation. Interestingly, we identi¢ed a
novel domain in BP75, the BYC domain (the conserved seg-
ment in BP75, YN92 and C01H6.7), with similarity to the
putative transcriptional regulatory protein YN92 from yeast.
Although the role for this domain is open for further study,
the presence of both the bromo and the BYC domain suggests
that BP75 may have a role in regulation of the chromatin
structure and/or transcriptional activity.
Is there compatibility between the behavior and putative
role of BP75 and that of PTP-BL? In contrast to BP75 and
the isolated BL-PDZ-I domain, full-length PTP-BL protein is
essentially exluded from the nucleus (Fig. 7, [18] ; E.C., un-
published observations), although in some cells, a nuclear lo-
calization can be observed in our experimental set-up. Inter-
estingly, also low levels of endogenous PTP-BL have been
found in nuclei of mouse keratinocytes (Derick G. Wansink,
unpublished work), leaving open the possibility of BP75 and
PTP-BL to physically interact. It is also possible that BP75
and/or PTP-BL shuttle between the cytosol and the nucleus,
coupling signal transduction processes at the cell cortex to
nuclear events or vice versa. In this light, it is interesting to
note that protein 4.1, which contains a FERM domain like
PTP-BL, is also located both at the cell membrane and in the
nucleus [44]. Furthermore, several other submembraneous
proteins like zyxin, ZO-1, L-catenin and plakophilins 2a and
2b are also found located in the nucleus [45^49]. Conversely,
Br140, another primarily nuclear bromodomain-containing
protein, was initially identi¢ed due to its co-puri¢cation with
an integrin [36]. Shuttling of proteins or protein complexes
between compartments may therefore form an important
pathway for coupling submembraneous signalling events to
nuclear activity. PTP-BL may organize the di¡erent compo-
nents necessary for such a mechanism via its PDZ motifs and/
or regulate the characteristics of associated proteins by its
catalytic activity. Clearly, understanding the function of
BP75 awaits a better understanding of PTP-BL as a potential
sca¡old protein and therefore, it will be essential to obtain
more knowledge about the biological signi¢cance of PTP-BL
for example by using knock-out mouse models.
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